Atrial fibrillation (AF) is the most common cardiac arrhythmia. As an independent predictor of cardiovascular mortality, particularly for stroke, its management is a real public health issue. AF is associated with diabetes, obesity, hypertension, heart failure and, occasionally, hyperthyroidism. Atrial fibrosis is one of the major players in the genesis and maintenance of AF. It has a strong impact on rhythmic prognosis and treatment success. Currently the AF ablation is the treatment recommended by the European Society of Cardiology (ESC) and by the American Society of Cardiology. The rate of AF recurrence is variable according to the patient characteristics and remains unfortunately today difficult to predict. Abnormal concentrations of circulating biomarkers reflecting the underlying pathophysiologic mechanisms of myocardial fibrosis could help to identify patients at higher risk of developing AF and/or AF recurrence after ablation. Thus, the development of simple, reliable and valid biological tests of atrial fibrosis would allow the clinicians i) to estimate the potential success of AF ablation; ii) to predict AF recurrence; iv) and to propose a AF personalized therapeutic approach. The main objective of PROFIB-AF study is to identify, among biological markers (ICTP, PICP, PIIINP, sRAGE, AGE, Galectin 3, sSt2, microRNAs) of myocardial fibrosis, those which can predict the recurrence risk after AF ablation.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at pre-ablation (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 3 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 6 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 12 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at pre-ablation (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 3 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 6 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: Any AF episode >30 seconds at 12 months (yes or no)
Occurrence of an atrial fibrillation recurrence
Timeframe: PIIINP at pre-ablation (in ng/mL
Occurrence of an atrial fibrillation recurrence
Timeframe: PIIINP at 12 months (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: ICTP at pre-ablation (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: ICTP at 12 months (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: PICP at pre-ablation (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: PICP at 12 months (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: sRAGE at pre-ablation (in pg/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: sRAGE at 12 months (in pg/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: AGE at pre-ablation (in ng/mL)
Occurrence of an atrial fibrillation recurrence
Timeframe: AGE at 12 months (in ng/mL)